(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 February 2013 (21.02.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/024095 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)

(21) International Application Number:
PCT/EP2012/065904

(22) International Filing Date:
14 August 2012 (14.08.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
11177660.5 16 August 2011 (16.08.2011) EP
61/523,862 16 August 2011 (16.08.2011) US

(71) Applicant *(for all designated States except US)*: **MORPHOSYS AG** [DE/DE]; Lena-Christ-Strasse 48, 82152 Martinsried/Planegg (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **AMERSDORFFER, Jutta** [DE/DE]; Lena-Christ-Str. 48, 82152 Martinsried / Planegg (DE). **STEIDL, Stefan** [DE/DE]; Ebenböckstr. 25, 81241 München (DE). **WINDERLICH, Mark** [DE/DE]; Implerstr. 52, 81371 München (DE). **KROHN, Susanne** [DE/DE]; Haidelweg 22a, 81241 München (DE). **ROJKJAER, Lisa** [CA/CH]; Frohmoosstrasse 38h, CH-8908 Hedingen (CH).

(74) Agent: **HUTTER, Bernd**; Lena-Christ-Str. 48, 82152 Planegg-Martinsried (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,


[Continued on next page]

(54) Title: COMBINATION THERAPY WITH AN ANTI - CD19 ANTIBODY AND A PURINE ANALOG

(57) Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

Figure 5

Normalized specific killing; SD; MEC-1 target cells pretreated with Fludarabine (Flu) for 72 h before ADCC; pool of 3 independent experiments with 3 different effector cell donors



The figure shows the averages from the data shown in Table 2.

WO 2013/024095 A1

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*